Corticosteroid Use in Childhood‐Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006–2022)
United European Gastroenterology Journal · 2026-03 · 14 (2)
DOI: 10.1002/ueg2.70160 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 05.03.2026. Verfasst von Karl Mårild und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Research Council, Region Stockholm.
Abstract (Originalsprache)
Background
We aimed to determine corticosteroid (CS) use in paediatric inflammatory bowel disease (PIBD, < 18 years), which remains common despite recommendations for limited use and the emergence of steroid‐sparing therapies.
Methods
We conducted a study of all children in Sweden diagnosed with CD ( n = 2460) or UC ( n = 2470) in 2006–2022. Nationwide health registers provided annual individual‐level data on CS use, classified as any use and excess use (i.e., ≥ 2 courses or ≥ 3 months of use per year).
Results
The mean age at diagnosis was 13.7 (SD = 3.4) for CD and 13.9 (SD = 3.8) years for UC. In CD, the proportion of patients with any annual CS use decreased from 42.9% (2006) to 27.6% (2022; p < 0.001), particularly for excess CS use (decreasing from 33.7% to 19.1%; p < 0.001). Rates in UC remained largely unchanged, with any CS use at 41.0% in 2006 and 43.6% in 2022 ( p = 0.43), while excess use was 32.4% in 2006 and 36.2% in 2022 ( p = 0.21). Although any CS use was most common during the first year after diagnosis (CD: 63.8%, UC: 70.6%), annual rates stabilised only during the fourth (CD) and fifth (UC) years of diagnosis. Older age at diagnosis and prior IBD‐related hospitalisation were risk factors for excess CS use in both CD and UC.
Conclusions
The use of CS in PIBD remains high, with annual rates showing no reduction in UC over the past more than 15 years, while a marked decline is observed in CD. Our data should inform strategies to reduce excess CS use in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden.
- Department of Paediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden.
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Amager Hvidovre Hospital, Hvidovre, Denmark.
- Copenhagen Centre for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital, Hvidovre, Denmark.
- Sachs' Children and Youth Hospital, Stockholm, Sweden.
- Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Karl Mårild, Mikkel Malham, Petter Malmborg, Tim Raine, Ola Olén
Förderung
- Swedish Research Council
- Region Stockholm
Zitieren
APA
Mårild, K., Malham, M., Malmborg, P., Söderling, J., Wewer, M. D., Wewer, V., SWIBREG Study Group, Raine, T., Burisch, J., & Olén, O. (2026). Corticosteroid Use in Childhood‐Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006–2022). United European Gastroenterology Journal, 14(2). https://doi.org/10.1002/ueg2.70160
Vancouver
Mårild K, Malham M, Malmborg P, Söderling J, Wewer MD, Wewer V, et al. Corticosteroid Use in Childhood‐Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006–2022). United European Gastroenterology Journal. 2026;14(2). doi:10.1002/ueg2.70160
BibTeX
@article{Mrild2026,
author = {Mårild, Karl and Malham, Mikkel and Malmborg, Petter and Söderling, Jonas and Wewer, Mads Damsgaard and Wewer, Vibeke and SWIBREG Study Group, SWIBREG Study Group and Raine, Tim and Burisch, Johan and Olén, Ola},
title = {Corticosteroid Use in Childhood‐Onset Inflammatory Bowel Disease: A Nationwide Cohort Study (2006–2022)},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/ueg2.70160}
}
EUVIMED